Market needs a better mousetrap than a PCR based test. The media is very transparent about the shortcomings of PCR as it relates to diagnostic testing.

Nnlx has an open door. We need to show that our technology works and we have a product application for COvid 19 and other pathogens. That’s the big IF. I do not think PCR dominance over channels of distribution for testing is a hurdle for much longer.